Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) widely investigated in preclinical models for its remarkable selectivity and potency. By binding specifically to the ghrelin receptor, ipamorelin stimulates natural pulsatile growth hormone release without driving unwanted surges in cortisol or prolactin.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) widely investigated in preclinical models for its remarkable selectivity and potency. By binding specifically to the ghrelin receptor, ipamorelin stimulates natural pulsatile growth hormone release without driving unwanted surges in cortisol or prolactin.
In contemporary ipamorelin research, this compound is classified as a selective synthetic pentapeptide growth hormone secretagogue (GHS) that targets the growth hormone secretagogue receptor (GHS-R1a). Preclinical investigations demonstrate that ipamorelin induces potent, pulsatile growth hormone release while displaying negligible affinity for receptors governing cortisol, adrenocorticotropic hormone (ACTH), prolactin, or aldosterone secretion.
Discovered as a second-generation growth hormone releasing peptide (GHRP), ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) was engineered to overcome the non-specific endocrine activation observed in earlier secretagogues. Researchers across biochemistry and endocrinology utilize purified ipamorelin 5mg vials to study somatotroph signaling pathways, receptor ligand kinetics, and metabolic responses in controlled in vitro and in vivo animal models.
The molecular architecture of ipamorelin consists of five amino acid residues, incorporating non-natural amino acids such as alpha-aminoisobutyric acid (Aib) and D-2-naphthylalanine (D-2Nal). These structural modifications render the peptide highly resistant to rapid enzymatic cleavage by central and peripheral peptidases, extending its terminal half-life during basic laboratory assays.
In competitive receptor-binding assays, ipamorelin acts as a full agonist at the ghrelin receptor (GHS-R1a). Upon binding, it triggers intracellular calcium mobilization via the phospholipase C (PLC) and inositol trisphosphate (IP3) signaling cascades. This molecular sequence stimulates signal transduction within pituitary somatotrophs, leading to vesicular exocytosis of endogenous growth hormone. Investigators evaluating molecular pathways often cross-reference these binding parameters within the broader PX1 peptide research hub.
Unlike non-selective secretagogues that induce sustained, non-physiological spikes in growth hormone, ipamorelin research highlights a distinct, pulsatile profile. In vitro perifusion studies using rat anterior pituitary cells demonstrate that ipamorelin induces a rapid, dose-dependent rise in growth hormone concentrations that mimics endogenous hypothalamic growth hormone-releasing hormone (GHRH) pulses.
Crucially, the mechanism operates synergistically with endogenous GHRH signaling. While GHRH activates the cyclic adenosine monophosphate (cAMP) pathway, ipamorelin operates through protein kinase C (PKC) pathways. When studied in combination, these dual pathways yield an additive somatotroph discharge without saturating pituitary receptor reserves or desensitizing GHS-R1a targets over short-to-medium experimental timeframes.
A defining feature established in preclinical literature is ipamorelin's lack of effect on non-target pituitary axes. First-generation GHRPs frequently trigger transient spikes in systemic cortisol and prolactin by cross-reacting with hypothalamic or central neuroendocrine receptors. In contrast, ipamorelin research consistently validates zero statistically significant elevation of ACTH, cortisol, prolactin, luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) at standard experimental concentrations.
This high degree of receptor specificity makes ipamorelin an exceptional control molecule in somatotroph research. Experimental designs assessing metabolic substrate utilization, nitrogen retention, or protein synthesis can isolate growth hormone-mediated pathways without confounding variable spikes in catabolic hormones like cortisol.
Preclinical evaluations in rodent models have investigated ipamorelin across several physiological vectors, including longitudinal bone growth, body composition, and gastrointestinal motility. In young, growth-retarded rat models, daily administration of ipamorelin led to significant dose-dependent increases in longitudinal bone growth rate and total body weight gain without altering serum insulin or glucose dynamics.
Furthermore, animal models examining postoperative ileus and bowel motility indicate that ghrelin receptor agonism by ipamorelin enhances gastric emptying and intestinal transit. Additional rodent studies highlight potential neuroprotective and osteogenic effects, where enhanced somatotroph signaling correlates with increased osteoblast activity and trabecular bone density. Researchers comparing these metabolic metrics often evaluate a broad range of catalogue research peptides to baseline secretagogue efficacy.
When designing comparative secretagogue protocols, researchers frequently evaluate ipamorelin alongside other classical GHRPs and GHRH analogs. A clear distinction emerges when comparing ipamorelin against GHRP-2 research compounds and GHRP-6 research models. While GHRP-2 exhibits high potency, it routinely induces marked increases in serum prolactin and cortisol, as well as appetite stimulation mediated by central ghrelin activation. GHRP-6 similarly triggers significant hyperphagia in rodent models.
Conversely, ipamorelin isolates somatotrope release without altering food intake or activating stress-axis biomarkers. When combined in dual-agonist protocols with GHRH analogs such as CJC-1295 without DAC or Sermorelin research reagents, ipamorelin produces a synergistic, amplified growth hormone pulse. This comparative profile is summarized in the matrix below:
To preserve chemical stability and prevent hydrolytic degradation, ipamorelin is supplied as a sterile, lyophilized cake. Reconstitution should be performed under a laminar flow hood using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline, depending on the requirements of the planned assay. The diluent should be introduced gently along the glass wall of the vial to minimize shear force and bubble formation.
Following reconstitution, liquid aliquots should be stored at 2°C to 8°C for short-term experimental windows (up to 28 days) or sub-zero (-20°C to -80°C) for long-term storage. Repeated freeze-thaw cycles must be avoided to prevent peptide aggregation and loss of bioactivity. Lyophilized vials remain stable at room temperature during transit but should be transferred to -20°C storage upon receipt.
Data integrity in preclinical research depends strictly upon chemical purity and lot-to-lot consistency. Low-grade research compounds containing synthesis side-products or residual trifluoroacetic acid (TFA) can skew receptor binding assays, induce cell toxicity, or generate anomalous experimental results.
PX1 Research enforces rigorous verification for every production lot. Every batch undergoes full spectrum analysis in an independent, ISO 17025 accredited laboratory using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify peptide purity exceeds 98.0%, alongside Liquid Chromatography-Mass Spectrometry (LC-MS) to confirm correct exact molecular mass.
Furthermore, every lot is subjected to Chromogenic Kinetic Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain well below critical thresholds (<0.01 EU/mg), ensuring clean baseline data for delicate cell culture and in vivo animal models.
PX1 Research is an established USA-manufactured supplier dedicated exclusively to supporting academic, biotechnology, and institutional laboratories. By adhering strictly to cGMP-compliant manufacturing processes and comprehensive quality assurance protocols, PX1 ensures that researchers receive fully characterized, highly reproducible compounds.
Every shipment includes a lot-specific Certificate of Analysis (COA) detailing HPLC chromatograms, mass spectra, and endotoxin assay results. Orders are fulfilled rapidly with same-day dispatch (Monday through Friday) originating from dual logistics hubs in California and Arizona. Principal investigators and lab managers establishing recurring research supply lines can explore bulk purchasing and institutional terms through our dedicated wholesale laboratory portal.
What is the primary role of ipamorelin in laboratory research?
Ipamorelin functions as a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist. It is studied in preclinical models to evaluate pulsatile growth hormone secretion, somatotroph signaling, bone density changes, and gastrointestinal motility.
Does ipamorelin stimulate cortisol or prolactin production in experimental models?
In vitro and animal studies consistently demonstrate that ipamorelin does not significantly elevate cortisol, ACTH, or prolactin levels, distinguishing it from less selective secretagogues like GHRP-2 or GHRP-6.
How is ipamorelin purity verified by PX1 Research?
Every lot of ipamorelin undergoes independent ISO 17025 laboratory testing using RP-HPLC to verify chemical purity above 98% and LC-MS to confirm exact molecular weight. Quantitative LAL assays are also conducted to ensure minimal endotoxin content.
What solvent is recommended for reconstituting ipamorelin for lab assays?
Reconstitution is typically carried out using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile 0.9% sodium chloride solution under aseptic laboratory conditions.
What are the optimal storage conditions for ipamorelin?
Lyophilized ipamorelin should be stored at -20°C for long-term stability. Once reconstituted into liquid solution, it should be kept refrigerated at 2°C to 8°C and used within 28 days, avoiding repeated freeze-thaw cycles.
How does ipamorelin compare to CJC-1295 in preclinical studies?
Ipamorelin is a ghrelin receptor agonist (pentapeptide), whereas CJC-1295 is a GHRH receptor agonist (tetrasubstituted peptide). Researchers frequently study them together because activating both distinct receptor pathways yields a synergistic pulse of growth hormone.
What are the endotoxin limits for PX1 Research compounds?
PX1 Research subjects all peptide lots to chromogenic LAL testing, enforcing strict endotoxin limits (<0.01 EU/mg) to prevent inflammatory artifacts during cell culture or animal research.
Can ipamorelin be used for human consumption or therapeutic administration?
No. Ipamorelin supplied by PX1 Research is strictly designated for in vitro, preclinical, and laboratory research use only. It is not for human or veterinary use, medical diagnosis, or therapeutic applications.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.